1 / 12

15/10/14

F2F meeting Sept 2016 Work from: Simon Lovestone ’s lab Presenting: Alejo J Nevado - Holgado. 1) Epidemiology correlated with JAK/STAT 2 ) A β/τ contrast enriches lipids and comp . 3) Lipid metabolism in A β / τ contrast (Alison Braid)

nluna
Download Presentation

15/10/14

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. F2F meeting Sept 2016 Work from: Simon Lovestone’s lab Presenting: Alejo J Nevado-Holgado 1) Epidemiology correlated with JAK/STAT 2) Aβ/τ contrast enriches lipids and comp. 3) Lipid metabolism in Aβ/τ contrast (Alison Braid) 4) Systematic analysis of drugs in real world data (Chi-Hun Kim) 15/10/14

  2. Epidemiology correlated with JAK/STAT

  3. Aβ/τcontrast enriches lipids and comp.

  4. Anti-inflammatories & better cognition

  5. Work status in WP1 • Publications funded by the consortium: • JAK-STAT correlates how protective inflammatory diseases are to Alzheimer’s disease. In preparation. • Pathways at the intersection of AD and NSAIDs. CSBJ. • Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open. • Enrichment of Aβ/τ contrast. In preparation. • Plan for next year, following SAB feedback • Study whether C-Map and epidemiology further support CSF1R, P2X7 & TYK2 • In future wet-lab validation, use co-cultures and positive controls

  6. C-Map and epidemiology: Strategy • US Ambulatory records: • 250K patients, 8 drugs max • Cmap: • ~1500 drugs, 3 lines

  7. C-Map and epidemiology: Strategy Gene – Drug associations Drug – AD associations Gene – AD

  8. Selecting relevant drugs in C-Map

  9. Selecting relevant diseases in EHRs

  10. Genes that are affected by drugs apparently protective for AD

  11. Work status in WP1 • Next steps • Compile a list of drugs affecting CSF1R and TYK2 to different degrees and directions • Increase the number of patients on the US Ambulatory Records, from 250K to 1M or more • Investigate whether TYK2-AD and CSF1R-AD effects are strongest in some types of patients, but weaker in others. • If results are positive, attempt wet-lab validation.

  12. Many thanks!

More Related